TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Feeding balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satisfaction with PoCT training
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Creatine kinase MB (CK-MB) release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for inotropic support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Normalization of the platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite outcome event (TTP-related death, recurrence of TTP, or thromboembolic event)
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of TTP
Endpoint domain: Adverse events/effects
Primary endpoint: CF rates for TQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PSs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: progression free survival at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Number of weekly incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (Incontinence Impact Questionnaire total score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average voided volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: lengths of stay in the intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: lengths of stay in the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: postoperative volume of drained blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean hemoglobin decrease 12 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of patients requiring blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean change-from-baseline weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of MTB in ocular tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in mean pre-test and post-test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plaque score percentage reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postischemic liver function parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative health perceptions of the e‐cigarette brand
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Warning recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: pupae per container
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: pupae per household
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Breteau index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative urinary retention (POUR)
Endpoint domain: Adverse events/effects
Primary endpoint: O2max improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LP strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic complications (e.g., pneumonia)
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle strength during spinal anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal function evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Average survival time
Endpoint domain: Mortality/survival
Primary endpoint: Likelihood of HIV testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: serum concentration of IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: total nasal resistances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of corneal endothelial cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: US Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: decrease in glycosylated hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of major maternal morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of new or recurrent HELLP syndrome episodes
Endpoint domain: Adverse events/effects
Primary endpoint: time to delivery or fetal death
Endpoint domain: Mortality/survival
Primary endpoint: Mean serum concentration of HGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: portal pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Understanding of the research process
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Postoperative myalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability of EP217609 and avidin
Endpoint domain: Adverse events/effects
Primary endpoint: neutralization of anticoagulant activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pressure pain threshold of the sternocleidomastoid muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG-BF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of ongoing pregnancies
Endpoint domain: Mortality/survival
Primary endpoint: Bronchoscopy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of p-selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma concentrations of D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Overall experience tolerability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Range of lateral uterine motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cul-de-sac exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure of fallopian tubes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal walking distance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamometry scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functionality scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of post-dose symptoms following ZOL infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to next platelet transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: tcpO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impulsive aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of vitreous hemorrhage recurrence
Endpoint domain: Mortality/survival
Primary endpoint: progression of lens opacities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Absolute loss in minimal lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative loss in minimal lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximal global pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial stiffness (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: voluntary quadriceps strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: six-minute walking test distance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality-of-life score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean condylar deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of endotoxin and cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality-of-life score (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak flow rate (PFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health status measured by KCCQ-OS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with excellent outcome (alive with KCCQ-OS ≥75 and no significant decline)
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in understanding of inherited soil sensitivity and susceptibility to podoconiosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decreased stigma-related attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increased perceived value of foot protection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean flare value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aqueous cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative symptom score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain experienced during humeral block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional Cerebral Blood Flow (rCBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of lymph nodes dissected around the left RLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Preference for hearing aid fitting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased attentional control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Need for additional inotropic support
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Oliguria, renal dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of death, nonfatal reinfarction, or thromboembolic cerebral stroke
Endpoint domain: Mortality/survival
Primary endpoint: improvements in liver biochemistries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: markers of cholestasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fidelity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Exposure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Responsiveness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement of hyperphagic behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of fast eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced decisional conflict
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive increments in autism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to disposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean quality of sedation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total cholesterol and low-density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of hypoglycemia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epinephrine responses after IDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak [F‐] after sevoflurane anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage increase in vein diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Heart rates intraoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional fentanyl
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of SV (Symptomatic Vasospasm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of CIV (Cerebral Infarction Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma Abeta(40) concentration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin and subcutaneous tissue concerns
Endpoint domain: Adverse events/effects
Primary endpoint: intraoperative requirements for additional analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative requirements for additional analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Cell growth index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum VEGF reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follistatin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Negative urine cultures on day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-associated complications
Endpoint domain: Adverse events/effects
Primary endpoint: Cost savings
Endpoint domain: Resource use
Primary endpoint: bladder pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bladder wall stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: voided volumes per urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Rating Scale (HAM-D-17) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptomatic AF burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seropositivity rates for anti-Vi antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seropositivity rates for anti-HAV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success rate of post-pyloric placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cho/Cr ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cho/NAA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean regenerated bone volume 6 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schirmer‐I test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BUT test value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of dizziness
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of hangover
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of impaired concentration
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of hallucinations
Endpoint domain: Adverse events/effects
Primary endpoint: Clotting phenomena necessitating premature termination of dialysis
Endpoint domain: Adverse events/effects
Primary endpoint: Mean dialyzer clotting scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instantaneous urea nitrogen clearances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LE Ashworth score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: UE Ashworth score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Significant restenosis cases
Endpoint domain: Adverse events/effects
Primary endpoint: Reported seeing the posters
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ratios of total and non-HDL cholesterol to HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean intention to screen scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mental health-related quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: histologic core procurement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraobserver and interobserver reliabilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of intraoperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noninvasive keratograph breakup time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescein breakup time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discriminative ability of NIKBUT in detecting dry eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of clinical syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for midazolam sedation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma venom concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in autism severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart failure hospitalization or all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Upregulation of Dkk‐1 skin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Downregulation of TGFβ expression in skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean duration of intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in fertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of deliveries at > or = 37 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: reductions in OCD-related beliefs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in OC symptom measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Output (UO) at postoperative day 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Cardiac Index (CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of Pediatric Cardiac Intensive Care Unit (PCICU) admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Angle of deviation of the knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in DCE-MRI parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in CT EnF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidences of local recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Upper body adipose tissue loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of EPA in plasma phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of DHA in plasma phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of arachidonic acid in plasma phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KCCQ improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DASI improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HBV-related hepatitis
Endpoint domain: Adverse events/effects